Stay updated on Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy
Sign up to get notified when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.

Latest updates to the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe page footer has been updated to reflect a newer ClinicalTrials.gov UI/site revision (v3.5.3 instead of v3.5.2). This represents a site maintenance/version change rather than a change to the study details.SummaryDifference0.0%

- Check24 days agoChange DetectedRevision: v3.5.2 replaces v3.5.0.SummaryDifference0.0%

- Check53 days agoChange DetectedAdded the 2026 Neurol Ther publication detailing EMBARK two-year outcomes and updated the revision to v3.5.0; the older online-ahead-of-print citation and its previous revision (v3.4.3) were removed.SummaryDifference0.1%

- Check60 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check74 days agoChange DetectedAdded a 2026 Neurol Ther publication by Audhya et al. on caregiver-reported experiences with Delandistrogene Moxeparvovec in EMBARK and removed the 2025 online-ahead-of-print Neurol Ther article.SummaryDifference0.0%

- Check88 days agoChange DetectedMinor site-wide updates were made, including adding revision v3.4.2 and removing notices about funding lapse and revision v3.4.1. These changes do not affect study data, eligibility, or user actions on the page; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Delandistrogene in Duchenne Muscular Dystrophy page.